News
Delta-Fly Pharma, Inc. completed the patients’ enrollment for the Phase 3 study of DFP-10917 and will start the 1st interim analysis for NDA approval.
Delta-Fly Pharma Inc.: Update for Development Status of the Combination Study of DFP-10917 with Venetoclax December 09, 2024 06:00 AM Eastern Standard Time ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback